Stifel Nicolaus Cuts Cue Biopharma (NASDAQ:CUE) Price Target to $4.00

Cue Biopharma (NASDAQ:CUE) had its price objective reduced by Stifel Nicolaus from $8.00 to $4.00 in a research report sent to investors on Tuesday morning, Benzinga reports. They currently have a buy rating on the stock.

Other analysts have also recently issued research reports about the stock. Piper Sandler reduced their price objective on shares of Cue Biopharma from $8.00 to $3.00 and set an overweight rating for the company in a research note on Friday, July 26th. JMP Securities cut their target price on shares of Cue Biopharma from $15.00 to $2.00 and set a market outperform rating for the company in a research report on Friday, July 26th. Five research analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock has a consensus rating of Buy and a consensus target price of $5.00.

Cue Biopharma Stock Down 9.9 %

Shares of NASDAQ CUE opened at $0.82 on Tuesday. The company has a quick ratio of 2.47, a current ratio of 2.47 and a debt-to-equity ratio of 0.11. Cue Biopharma has a 52 week low of $0.58 and a 52 week high of $3.25. The firm has a 50-day moving average price of $0.93 and a 200 day moving average price of $1.54. The stock has a market capitalization of $39.65 million, a price-to-earnings ratio of -0.77 and a beta of 1.96.

Cue Biopharma (NASDAQ:CUE) last announced its quarterly earnings data on Wednesday, August 14th. The company reported ($0.20) EPS for the quarter, beating the consensus estimate of ($0.29) by $0.09. Cue Biopharma had a negative net margin of 711.84% and a negative return on equity of 128.30%. The firm had revenue of $2.66 million during the quarter, compared to analysts’ expectations of $1.12 million. During the same quarter last year, the business earned ($0.29) earnings per share. Equities research analysts anticipate that Cue Biopharma will post -0.93 EPS for the current fiscal year.

Hedge Funds Weigh In On Cue Biopharma

A number of institutional investors have recently modified their holdings of CUE. Legacy Capital Group California Inc. acquired a new position in shares of Cue Biopharma in the fourth quarter valued at approximately $26,000. Wedmont Private Capital raised its position in shares of Cue Biopharma by 100.0% in the first quarter. Wedmont Private Capital now owns 40,000 shares of the company’s stock valued at $76,000 after buying an additional 20,000 shares during the last quarter. Vanguard Group Inc. raised its position in shares of Cue Biopharma by 7.1% in the first quarter. Vanguard Group Inc. now owns 2,283,362 shares of the company’s stock valued at $4,316,000 after buying an additional 150,457 shares during the last quarter. Finally, Point72 Asia Singapore Pte. Ltd. acquired a new position in shares of Cue Biopharma in the second quarter valued at approximately $66,000. Institutional investors and hedge funds own 35.04% of the company’s stock.

About Cue Biopharma

Cue Biopharma, Inc, a clinical-stage biopharmaceutical company, develops a novel class of injectable therapeutics to selectively engage and modulate targeted, disease relevant T cells directly within the patient's body. Its lead drug product candidate is CUE-101 for the treatment of human papilloma virus (HPV16+)-driven recurrent/metastatic head and neck cancer.